Quarterly report pursuant to Section 13 or 15(d)

Business, Presentation and Recent Accounting Pronouncements (Details)

v3.24.3
Business, Presentation and Recent Accounting Pronouncements (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2024
USD ($)
Jun. 11, 2024
shares
Jan. 31, 2024
performance_obligation
Sep. 30, 2024
USD ($)
shares
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2023
USD ($)
Jun. 10, 2024
shares
May 01, 2024
shares
Dec. 31, 2023
USD ($)
shares
Subsidiary, Sale of Stock [Line Items]                      
Cash and cash equivalents       $ 5,637,019     $ 5,637,019       $ 2,454,684
Short-Term Investments       23,398,016     23,398,016       0
Accumulated deficit       (139,158,620)     (139,158,620)       $ (146,976,855)
Number of performance obligations | performance_obligation     1                
Proceeds from collaborators         $ 16,000,000            
In-Process R&D Impairment $ 2,000,000     $ 2,008,000   $ 1,904,314 $ 2,008,000 $ 1,904,314      
Reverse stock split, conversion ratio   0.111111111111111                  
Common stock, shares authorized (in shares) | shares   150,000,000   150,000,000     150,000,000     150,000,000 50,000,000
Common stock, shares, outstanding (in shares) | shares   2,970,545   3,000,788     3,000,788   26,735,116   856,182
In Process Research and Development                      
Subsidiary, Sale of Stock [Line Items]                      
In-Process R&D       $ 6,700,000     $ 6,700,000       $ 8,700,000